2nd Annual Clinical Trials in Oncology
6th - 7th October 2011, Rome, Italy

Attend this event to explore effective strategies to gain competitive advantage and understand the role of safety biomarkers in clinical development. Leading Pharma companies will share first hand experience with adaptive trial designs and case studies on optimising trial development in order to speed approval time and improve operational efficiency.

Key speakers:
Vice President, Chief Clinical Officer, Teva, Israel
Senior VP Oncology, Celgene, USA
Head Molecular Profiling, Translational Medicine Research Centre Singapore, MSD, Singapore
Chief Medical Officer, Aslan Pharmaceuticals, UK
Director Experimental Medicine Oncology, MSD, The Netherlands
Medical Director, Ipsen, Italy

Reasons to attend:
Meet leading oncology Pharma representatives
Discuss effective patient retention and compliance strategies
Understand the current challenges of conducting clinical trials in emerging markets
Gain valuable information about the role of molecular imaging biomarkers in oncology clinical trials
Extend your knowledge recent developments in regulatory clinical trials in the EU
Explore the use of social media to recruit patients for cancer clinical trials
Learn about opportunities and challenges in translational biomarker research
Benefit from interactive discussions with your peers to benchmark your experience

For further information visit: http://pharma.flemingeurope.com/oncology-market-access/ or contact Martina Izak on martina.izak@flemingeurope.com or +421 257 272 137.